that TSG101 is mutated at high frequency in human uncultured primary human breast carcinomas, intrabreast cancer and further suggest that defects in genic deletions were shown in TSG101 genomic DNA TSG101 occur during breast cancer tumorigenesis and/ and transcripts by gel and sequence analysis, and muor progression. tations affecting two TSG101 alleles were identified in four of these cancers. No TSG101 defects were found in matched normal breast tissue from the breast canResults cer patients. These findings strongly implicate TSG101 mutations in human breast cancer.
Introduction gene-discovery approach (Random Homozygous Knock Out [RHKO] ) that enables regulated functional inactivatsg101 is a recently discovered tumor susceptibility gene whose functional knockout in mouse fibroblasts tion of multiple copies of previously unknown genes and selection for cells that show a phenotype resulting from leads to transformation and the ability to form metastatic tumors in nude mice (Li and Cohen, 1996) . The cellular such inactivation (Li and Cohen, 1996) . Using the 1448 bp mouse cDNA sequence to query the dbEST (Extransformation and tumorigenesis that result from inactivation of tsg101 is reversible by restoration of tsg101 pressed Sequences Tags) database of the National Center for Biotechnology Information (NCBI) by the BLAST function, suggesting that tsg101 acts to suppress malignant cell growth. Sequence analysis of mouse tsg101 program, ten human partial cDNA sequences that showed 85%-95% identity to mouse tsg101 cDNA were cDNA indicates that the gene encodes a 43 kDa protein containing a proline-rich domain and DNA-binding modetected (Figure 1Aa ). Primers corresponding to a sequence contained within a region of identity between tifs characteristic of transcription factors. Additionally, the TSG101 protein encodes a coiled-coil domain that ESTs H53754 and Z30135 (Pa-UDG and Pd-UDG) ( Figure  1Ab ) and to sequences bracketing the vector cloning interacts with stathmin (Sobel, 1991) , also known as oncoprotein 18 , a cytoplasmic site of a gt10-based human cDNA library were used to amplify by PCR the 5Ј (Pc-UDG and Pd-UDG) and 3Ј (Paphosphoprotein elevated in a variety of malignancies and implicated in the regulation and relay of diverse UDG and Pb-UDG) segments of human TSG101 cDNA, employing total cDNA from the library as template (Figsignals associated with cell growth and differentiation (Hanash et al., 1988; Sobel, 1991; ure 1Ab) . The longest 5Ј and 3Ј PCR products were then joined in the UDG cloning vector pAMP1. Roos et al., 1993) .
We report here the cloning and mapping of the human A 1494 bp cloned human cDNA insert (tentatively termed "full-length" TSG101 cDNA), which was 86% TSG101 gene and the occurrence of TSG101 mutations in human breast cancer. Fluorescence in situ hybridizaidentical to mouse tsg101 cDNA at the nucleotide level, contained a 1140 bp open translational reading frame tion (FISH), radiation hybrid mapping, and analysis of somatic cell hybrids localized TSG101 to human chropredicted to encode a 380 amino acid protein with a molecular mass of 42.841 kDa and a pI of 5.87 (Figure mosome 11, subbands p15.1-15.2, a region showing loss of heterozygosity (LOH) in a variety of human malig-1B). The predicted mouse and human proteins are 94% identical and are distinguished by 20 amino acid misnancies, primarily breast cancers (e.g., Ali et al., 1987; Winqvist et al., 1993) and proposed previously to contain matches and one gap ( Figure 1B . UDG primers Pa-UDG and Pd-UDG employed a 27 bp sequence within a region of 100% identity between ESTs H53754 and Z30135. These, plus two other UDG primers (Pb-UDG and Pc-UDG) corresponding to sequences bracketing the vector cloning site of a gt10-based human placenta cDNA library (ATCC), were used to amplify by PCR the 5Ј (Pc-UDG and Pd-UDG) and 3Ј (Pa-UDG and Pb-UDG) segments of human TSG101 cDNA (b) using total DNA isolated from a human cDNA library as template. The longest 5Ј and 3Ј PCR products were joined in the UDG cloning vector pAMP1. (B) Human and mouse TSG101 protein sequence alignment. Amino acid sequences of the human and mouse TSG101 proteins were predicted from TSG101 and tsg101 cDNA open reading frames determined by cDNA sequence analysis. The positions of mismatches and a gap between human and mouse TSG101 are indicated with shaded minus sign (Ϫ). The predicted coiled-coil domain is shaded, and the amino acid positions defining a leucine zipper motif within the coiled-coil domain are boxed. N-terminal to the coiled-coil domain is a proline-rich domain shown by the amino acid designation for proline (P) in bold type.
activation domain of transcription factors (Mitchell and 38, 210, 249, 265, and 290) , and three potential N-glycosylation sites (aa 44, 150, and 297) . Analysis of the huTjian, 1989) are highly conserved between human and mouse TSG101, with only one amino acid mismatch in man TSG101 cDNA and protein sequences by a BLAST program search of the NCBI database showed no signifieach of the two domains. The leucine zipper motif in the coiled-coil domain of the human TSG101 protein is cant homology to any other known human gene sequence. identical to the one in the mouse protein ( Figure 1B ). Other features conserved between human and mouse A multiple-tissue Northern blot probed with full-length TSG101 cDNA showed a single 1.5 kb transcript in all TSG101 include seven putative protein kinase C phosphorylation sites (aa 11, 38, 86, 89, 215, 225, and 357 ), eight human tissues tested (Figure 2 ). Multiple-tissue blots for Northern blot analysis were purchased from Clontech. Blots contained 2 g of polyadenylated RNA in each lane and were hybridized with single-strand full-length TSG101 cDNA probe. Following hybridization, blots were stripped and rehybridized with a probe for human ␤-Actin mRNA as a control for loading. The positions of molecular-length markers and of the TSG101 and ␤-Actin transcripts are shown.
had isolated does, in fact, correspond to essentially fulllength native TSG101 mRNA.
Chromosomal Localization of Human and Mouse TSG101 Genes
Two PCR primers that specifically amplify a sequence from the 3Ј-untranslated region of human TSG101 cDNA (see Experimental Procedures) were used to analyze genomic DNA from a panel of 18 human ϫ Chinese hamster hybrid cell lines. A 210 bp PCR product was generated from DNA from human cells and from hybrid cell lines that contained human chromosome 11, but not from hamster DNA; it also was obtained from DNA (Francke, 1994) illuschromosomes, the human TSG101 gene was assigned trating the localization of human TSG101 by somatic cell hybrids to chromosome arm 11p.
(SCH), FISH, and radiation hybrid (RH) mapping. Distances between the STS markers (in centiRays) and lod scores (in parentheses) were
Screening of a PAC library of human genomic DNA calculated using a two-point linkage program. using the TSG101-specific forward and reverse primers indicated in Experimental Procedures yielded two overlapping clones, PAC1 and PAC2, each containing an insert 150 kb in length. These were shown to contain identified the position of this gene relative to polymorphic markers on the linkage map. Eleven of the 83 RH TSG101 human genomic DNA by Southern blotting using a 5Ј human TSG101 cDNA fragment as probe. FISH of cell lines showed a positive signal (retention frequency 13.25%) that by two-point linkage analysis was found each PAC clone to human chromosome spreads gave a signal on chromatids of both copies of chromosome to be closely linked to RH map Bin17 markers, and specifically to sequence-tagged site (STS) markers 11 in 20 metaphase cells analyzed ( Figure 3A) . Based on the chromosomal R-banding pattern, TSG101 is as-D11S921 through D11S1308 ( Figure 3B ). Both D11S921 and D11S1308 are on the Whitehead Institute integrated signed to chromosome 11 subbands p15.1-p15.2.
Radiation hybrid (RH) mapping using the Stanford G3 map and radiation hybrid map, and their physical positions correspond approximately to 11p15. A cluster of human RH mapping panel independently demonstrated the map location of the human TSG101 gene and also serum amyloid A (SAA) genes closely linked to these R E T R A C T E D markers has been mapped physically to subband 11p15.1 (Sellar et al., 1994) , placing TSG101 in the region encompassed by subbands 11p15.1-15.2. We also determined the map location for the mouse tsg101 gene and found it to be consistent with assignment of the human TSG101 gene to 11p15. PCR analysis of a mapping panel of 22 mouse ϫ rodent hybrid cell lines using mouse gene-specific primers showed that the PCR product was in complete concordance with the presence or absence of mouse chromosome 7 in these hybrid cell lines. All other mouse chromosomes were excluded by at least three discordant hybrids (data not shown). Given the known conserved syntenic regions on human chromosome 11p and mouse chromosome 7, the location of the mouse gene supports the conclu- , 1996) . the TSG101 protein-coding region ( Figure 4A ), of tran-TSG101 Mutations in Human Breast Cancers scripts from 15 primary breast cancers and matched Extensive studies have shown deletion or loss of heteronormal breast tissue showed deletions in TSG101 tranzygosity at or near the 11p15 band in a variety of human scripts in seven of these tumors but no abnormality in malignancies, primarily breast cancers (e.g., Ali et al.,
TSG101 transcripts from the normal breast tissue ( Figure  1987 ; Winqvist et al., 1993) , but also Wilms' tumor 4 and Table 1 ). Sequence analysis of the truncated cDNA (Dowdy et al., 1991; Cowell et al., 1993) and ovarian and fragments resulting from deletions in TSG101 trantesticular malignancies (Lothe et al., 1993; Weitzel et al., scripts and of the corresponding regions of transcripts 1994), suggesting that this region contains one or more from each matched normal breast tissue specimen (Figtumor suppressor gene(s) that are mutated or deleted ure 5) indicated the sites of the deletion junctions and in these cancers. Approximately 30% of 171 sporadic consequently identified the endpoints of the deletions. primary breast cancers analyzed showed loss of heteroThese are summarized in Table 1 . zygosity in a region mapping between 11p15.4 and The deletions occurring in the tumors of all breast 11pcen (Seizinger et al., 1991) . The notion that the short cancers except P5 directly eliminated all or part of the arm of chromosome 11 contains a tumor suppressor TSG101 transcript segment encoding the coiled-coil dogene implicated in the pathogenesis of human breast main, which is specified by nt 810-1022 of the transcript cancer is further supported by evidence that introducing ( Figure 1B ). The deletion in P5 is predicted to remove a normal chromosome 11 or segments of this chromo-200 aa (codons 6-205) upstream from the coiled-coil some into breast cancer cells reverses their metastatic domain and to generate, after codon 205, a frameshift potential, as well as other properties associated with leading to premature termination of the TSG101 protein oncogenesis (Koi et al., 1993; Negrini et al., 1995;  Phillips one codon later. Three of the seven primary breast canet al. , 1996) . The finding that inactivation of tsg101 concers showing deletions in TSG101 transcripts produced verts mouse fibroblasts into metastasizing cancer cells two different truncated transcript species, implying the (Li and Cohen, 1996) indicates that this gene may funcoccurrence of lesions in both TSG101 alleles in these tion as a suppressor of malignant cell growth. Our mapcancer cells. Remarkably, identical 921 bp deletions asping of human TSG101 to a region of chromosome 11 sociated with identical 63 bp insertions at the deletion implicated in human breast cancer led us to investigate junctions were observed in transcripts from breast cana possible role for TSG101 in breast tissue malignancy.
cers P4 and P7. Other transcripts encoded by tumor P7 We examined cDNA from 15 uncultured primary human included a 902 bp deletion in the same region, but lacked breast cancers specifically for mutations in TSG101, the 63 bp insertion. The presence of both an insertion comparing breast cancer transcripts (i.e., cDNA) and and a deletion in the same transcript suggests that multibreast cancer genomic DNA with transcripts and genople mutational events may occur in TSG101 during tumic DNA obtained from matched normal breast tissue morigenesis or progression of primary breast cancers. from the same patients.
Analogous evidence for multiple mutations or DNA rearrangements at the TSG101 locus was obtained for RT-PCR amplification, using primers that bracketed Genomic DNA and cDNA obtained from 14 primary breast cancers and matched normal breast tissue from the same patients were analyzed, and only cDNA was analyzed for a fifteenth breast cancer and matched normal control. The length of genomic DNA deletions was calculated by subtracting the length of truncated TSG101 DNA, as detected by Southern blotting, from the chromosomal DNA distance between primers Pr5 and Pr6 (determined as 15.4 Kb from the structure of the TSG101 genome locus) ( Figure 7 ). The point mutation in the nondeleted allele was identified by sequencing of the DNA fragment generated by PCR using primers Pr7 and Pr8, confirmed by the ablation of a BbsI restriction endonuclease cleavage site as a result of the mutation (Figure 8 ). a Surgical pathology diagnosis. b The T-to-C mutation changing Val to Ala. c The similarly-sized deleted genomic DNA bands for these two alleles were not distinguished, as noted in the text.
genomic DNA (see below). Nondeleted TSG101 tran-A search for point mutations in the coiled-coil region of the nondeleted TSG101 alleles of tumors P1, P3, and scripts were also present in all of the primary breast cancers we analyzed, consistent with the presence of P5 by sequencing of PCR-amplified exons 3, 4, and 5 of TSG101 genomic DNA (see Figure 7 ) using intron nontumor cells in these cancer specimens, as has been described previously for other malignancies (e.g., Sozzi primers (see Experimental Procedures) showed a T-to-C point mutation at bp position 1162 in the nondeleted et al , 1996) .
Genomic DNA was available for 6 of the the 7 primary allele of P1 ( Figure 7 and Table 1 ). This was identified by sequencing the 375 bp PCR-amplified genomic DNA breast cancers producing abnormal TSG101 transcripts. Southern blotting of PCR-amplified genomic DNA from fragment. Restriction enzyme analysis of this fragment confirmed the loss of a BbsI site, which was eliminated all 6 breast cancers showed truncated TSG101-specific DNA fragments resulting from genomic deletions that by the T-to-C transition, at the site of the mutation (Figure 8 ). As described above, tumor P7 produced two were not present in DNA from matched normal breast tissue from the same patients (Figures 6 and 7) . While separate TSG101 transcript species containing deletions (Figures 4 and 5 ; Table 1 ). While these deletions these truncated genomic DNA fragments were in most instances of the size expected from deletion of exon were similar in length, one of the deleted transcripts and intron sequences located between the endpoints had a 63 bp insertion identical to the insertion found of the cDNA deletions we had mapped by gel analysis in transcripts of tumor P4. As the 3 kb PCR-amplified and sequencing, in some tumors our genomic DNA analgenomic DNA fragments generated in tumor P7 by these ysis suggested that multiple deletions and/or insertions events were similar to each other in size, they were had occurred at the TSG101 locus.
not distinguished by gel analysis in the present studies. Evidence of TSG101 mutations in both alleles was Thus, lesions in two TSG101 alleles were demonstrated obtained by genomic DNA analysis for 3 of the 7 breast by both genomic DNA analysis and cDNA analysis for cancers. The genomic DNA deletion in one allele of P4 three of the six primary breast cancers showing TSG101 was the size expected from the cDNA deletion endabnormalities and by cDNA analysis in a fourth tumor. points; mutation of the second allele produced two truncated bands, suggesting that sequences within an intron Discussion amplified by primers Pr5 and Pr6 (Figure 7 ), but external to the deletion detected by the cDNA analysis (primers The malignant changes that result from functional inactiPr3 and Pr4, Figure 4A) were also absent or rearranged vation of tsg101 in mouse fibroblasts previously impliduring tumorigeneis or progression of this cancer. In cated the loss or disruption of tsg101 function in tumoriprimary breast cancer P2, which had shown deletions genesis (Li and Cohen, 1996) . Our present results map of two different lengths in TSG101 cDNA, genomic DNA the human TSG101 gene to chromosome 11p15, a site fragments of the sizes expected from cDNA analysis were observed for both deletions. in a variety of human cancers, particularly breast cancer regulating cell proliferation and differentiation. All of the TSG101 deletion mutations we identified removed all or (Seizinger et al., 1991; Bieche and Lidereau, 1995) . They further show that this gene and its transcripts are abnorpart of this domain, suggesting its relevance to the ability of TSG101 to suppress malignant cell growth. The point mal in human breast cancer. No TSG101 abnormalities were observed in transcripts or genomic DNA from mutation discovered at TSG101 bp 1162 in the nondeleted allele of tumor P1 is predicted to result in an amino matched normal breast tissue from breast cancer patients.
acid change from Val to Ala at one of the putative protein kinase C phosphorylation sites of the TSG101 protein. Both the mouse and human TSG101 proteins contain a coiled-coil domain nearly identical to one shown to
The presence of DNA-binding motifs in the TSG101 protein and a proline-rich region near the leucine zipper interact with stathmin (Maucuer et al., 1995) , also known as oncoprotein 18 (Marklund et al., 1993) , a phosphopro-DNA-binding motif suggests that TSG101 may be a transcription factor that is a downstream effector of stathmin tein proposed to coordinate and relay diverse signals R E T R A C T E D (Figure 5 continued) action. Whether a mutation in two TSG101 alleles, which conserved. Chromosomal mapping of TSG101 to human chromosome 11 and mouse chromosome 7, which share was shown for genomic DNA of three of the breast cancers we studied and by cDNA analysis in a fourth, is conserved syntenic regions, supports the conclusion that the human gene we have cloned is the true human required for breast cancer tumorigenesis, or whether a single coiled-coil domain-disrupting mutation can act homolog of mouse tsg101. Frequent abnormalities at 11p15 have been identified in concert with a mutation in some other gene in breast cancer, is not known.
in human breast cancers (Ali et al., 1987; Mackay et al., 1988; Ferti-Passantonopoulou et al., 1991 ; Chen et al., The extraordinary conservation between the mouse and human TSG101 proteins is consistent with the no-1992; Miyagi et al., 1992; Takita et al., 1992; Winqvist et al., 1993 Winqvist et al., , 1995 Gudmundsson et al., 1995; Karnik et al. , tion that this gene, which was unknown until recently, has an important biological role: the coiled-coil and pro-1995; Negrini et al., 1995) and also in a variety of other human cancers, including lung cancer (Ludwig et al., line-rich domains are highly similar in the mouse and human proteins, and additionally, the potential phos-1991; Fong et al., 1994; Kondo, et al., 1994) , testicular cancer and male germ cell tumor (Lothe et al., 1993 ; phorylation and N-glycosylation sites are completely
R E T R A C T E D
Studies of families showing early-onset breast cancer, which represents 5-10% of all breast malignancies, have led to the identification of two candidate breast cancer suppressor genes, BRCA1 and BRCA2 Wooster et al., 1995) . A role for these genes in the remaining 90-95% of (sporadic) breast cancers has not been established, and accumulating evidence indicates that mutations in the BRCA1 and BRCA2 genes are infrequent in breast cancer cells themselves Lancaster et al., 1996; Miki et al., 1996; Teng et al., 1996) . In contrast, genomic DNA deletions in TSG101 were detected by us in more than 40% of the primary breast cancers we analyzed. The absence of detectable TSG101 mutations in DNA from normal breast tissue from patients that were the source of the primary breast tumors we examined implies that deletion of TSG101 occurred during or following tumorigenesis and consequently is not likely to be linked to familial breast cancer. The current study has not investigated breast cancerprone families for possible abnormalities in TSG101.
All of the breast cancers we studied had metastasized, although the tumors analyzed were obtained from the primary site in human breasts. Breast cancer cell lines lacking a DNA region that we now know contains the TSG101 gene have been shown to have high metastatic Figure 6 . Southern Blot Analysis of PCR-Amplified Genomic DNA potential in nude mice (Zhang et al., 1991) . This observa- , 1996) , Wilms' tumor (Dowdy et al., 1991; Cowell et al., 1993) , ovarian cancer (Weitzel et al., 1994) , bladder cDNA and Genomic DNA Cloning Two UDG-primers (Booth et al., 1994) derived from ESTs H53754 cancer (Presti et al., 1991; Brewster et al., 1994) , myeloid and Z30135 are Pa-UDG (5Ј AGGUCAUGAUUGUGGUAUUUGGAG leukemia , malignant astrocyto- (Dowdy et al., 1991) , and a gene (named HTS1 or ST5) isolated and both strands of the cDNA inserts were sequenced using that may be responsible for suppressing tumorigenicity Sequenase 2.0 (USB).
in HeLa cells has been mapped to 11p15 (Lichy et al.,
The PCR product made using primers, 5Ј CTGATACCAGCTGGAG 1992). The sequence of the putative translation product GTTGAGCTCTTC 3Ј (forward primer) and 5Ј ATTTAGCAGTCCCAAC ATTCAGCACAAA 3Ј (reverse primer) were used to screen a PAC of this gene has no resemblance to TSG101. Figure 7 . Endpoints of TSG101 Mutations in Primary Breast Cancers Schematic map of region of human genomic DNA containing the TSG101 gene. The tentative genomic DNA structure of TSG101 was determined from PAC 1 using the method described by Riley et al, 1990 and Derry et al, 1995) . The lengths and positions of exons (numbered boxes) and the locations and approximate lengths of identified introns (horizontal lines) are shown. The locations of primers Pr5 and Pr6 used for PCR amplification of segments of TSG101 genomic DNA are indicated, as are the locations of TSG101-specific hybridization probes (H1 and H2) used for Southern blot analysis of PCR-amplified DNA. The fragments produced by genomic DNA deletions are shown in Figure 6 . The positions shown here for exonic endpoints of the deletions are based on the TSG101 genomic DNA structure and the TSG101 cDNA sequences determined for each tumor. The 63 bp insertions found in the cDNA of tumors P4 and P7 are shown schematically by diagonal lines and are not drawn to scale. library containing human genomic DNA inserts (Genome Systems, Chinese hamster and two mouse ϫ rat somatic-cell hybrid lines derived from four independent fusion experiments as described Inc.), yielding two overlapping clones, PAC1 and PAC2, each containing inserts about 150 kb long. The presence of TSG101-specific previously (Li et al., 1993) . The PCR primers used to amplify human and murine TSG101/tsg101 sequences were derived from the 3Ј sequences within these inserts was confirmed by Southern blotting, using a 5Ј fragment of human TSG101 cDNA as probe.
untranslated region: the human primers were those employed to clone TSG101 genomic DNA (see above). The murine primers were: 5Ј GAGACCGACCTCTCCGTAAAGCATTCTT3Ј (forward primer) and Primary Breast Cancers and Matched Normal Breast Tissue Fourteen primary breast tumors and matched normal breast tissue 5Ј TAGCCCAGTCAGTCCCAGCACAGCACAG 3Ј (reverse primer). PCR conditions were 95ЊC for 2.0 min; then 35 cycles of 94ЊC for from the same patients were obtained from Cooperative Human Tissue Network (Eastern, Southern, and Western divisions). Breast 0.5 min; 68ЊC for 0.5 min; 72ЊC for 1.0 min; followed by 72ЊC for 7.0 min To distinguish the PCR products from human and hamster cancer cDNA and cDNA from matched normal breast tissue for P6 were purchased from Biochain Institute, Inc. (San Leandro, CA).
sequences in some of hybrid lines, SSCA was carried out as described previously (Li et al., 1995b) . Multitissue Northern Blot Analysis of TSG101 Expression A Northern blot filter containing mRNA isolated from normal human tissues was purchased (Clontech). Radioactively-labeled single anti-TSG101 Gene Mapping For fluorescence in situ hybridization, two genomic DNA clones sense strand DNA probe generated from full-length human TSG101 cDNA by 40 cycles of primer extension, using [ 32 P]dCTP, was hybrid-(PAC1 and PAC2) carrying 150 kb inserts, each containing overlapping human TSG101 sequences, were labeled with biotin-11-dUTP ized to the filter using standard methods. The same blot was stripped and hybridized with a human ␤-actin probe synthesized by random by nick translation using commercial reagents (Boehringer Mannheim). Probes were hybridized at a concentration of 200 ng/50 ml priming as internal loading control.
per slide to pretreated and denatured metaphase chromosomes from human lymphocytes, and signals were detected, amplified, Somatic Cell Hybrids, PCR Amplifications, and SSCA The chromosome carrying the human TSG101 gene was identified and analyzed as described previously (Li, et al., 1995a) . The Stanford G3 radiation hybrid mapping panel consisting of using a panel of 18 human ϫ Chinese hamster hybrid cell lines derived from several independent fusion experiments (summarized 83 RH clones of the entire human genome with a resolution of approximately 500 kb was purchased from Research Genetics, Inc. in Francke et al., 1986) . The murine tsg101 gene was mapped to a mouse chromosome by analyzing a mapping panel of 20 mouse ϫ All 83 RH cell lines were typed for the human TSG101 gene by using
and DNA fragments were cut from gels and purified using QIA quick gel extract kit (Qiagen). Primers Pr7 and Pr8 (see Experimental Procedures) were used for References PCR amplification of a 375 bp fragment of exon 5 of TSG101 genomic DNA. The amplified fragment was purified from an agarose Ali, I.U., Lidereau, R., Theillet, C., and Callahan, R. (1987) . Reduction gel, digested with BbsI restriction endonuclease, and the projecting to homozygosity of genes on chromosome 11 in human breast neosingle-strand ends were filled in using the Klenow fragment of E.
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cle-invasive transitional cell carcinoma of the bladder. Br. J. Cancer (5Ј CCTCCAGCTGGTATCAGAGAAGTCGT 3Ј) were used for first 70, 697-700. PCR amplification for 25 cycles. The amplified products were diluted Byrne, J.A., Simms, L.A., Little, M.H., Algar, E.M., and Smith, P.J. 50-fold, and 1 l of the diluted product was used for a second round (1993) . Three non-overlapping regions of chromosome arm 11p alof PCR amplification for 30 cycles using two nested primers, P3 lele loss identified in infantile tumors of adrenal and liver. Genes (5Ј AGCCAGCTCAAGAAAATGGTGTCCAAG 3Ј) and P4 (5Ј TCACTG Chromosomes Cancer 8, 104-111. AGACCGGCAGTCTTTCTTGCTT 3Ј). PCR amplifications were carChen, L.C., Kurisu, W., Ljung, B.M., Goldman, E.S., Moore, D., and ried out in 50 l final volume of 20 mM Tris-HCl [pH 8.55], 3.3 mM Smith, H.S. (1992) . Heterogeneity for allelic loss in human breast MgCl 2 , 16 mM (NH 4 ) 2 SO 4 , 150 g/ml BSA, 300 M each dNTP, 0.2 cancer. J. Natl. Cancer Inst. 84, 506-510. l of KlentaqLA (Barnes, 1994) , in a Perkin-Elmer/Cetus thermal cycler at 95ЊC for .75 min (for denaturation), at 65ЊC for 0.5 min (for Cowell, J.K., Groves, N., and Baird, P. (1993). Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations annealing), and extension at 72ЊC for 0.5-1.5 min. The PCR products were resolved in 1.5% agarose gel stained with ethidium bromide, in the WT1 gene. Br. J. Cancer 67, 1259-1261.

